About virio emici zuma b
Bispecific factor IXa/X coagulation antibody
Used for
- Prevention of bleeding in hemophilia A, with or without factor VIII inhibitors.
Usual adult dose
Usually 3 mg/kg under the skin weekly for four weeks, then 1.5 mg/kg weekly, 3 mg/kg every two weeks, or 6 mg/kg every four weeks.
Usual dose in children
Same weight-based schedules as adults; used in children of all ages, including infants.
Common side effects
- Injection-site reactions
- Headache
- Joint pain
- Diarrhea
Important warnings
- Breakthrough bleeding may still occur; additional treatment may be needed.
- Combining with activated prothrombin complex concentrate can cause serious blood clots or tissue damage.
- Laboratory tests using clot-based methods may give misleading results.
- Serious allergic reactions are possible.
Pregnancy
Human pregnancy information is limited. Use during pregnancy only when clearly needed; discuss effective contraception during treatment.
Breastfeeding
It is unknown whether emicizumab passes into breast milk. Discuss potential benefits and risks with a healthcare professional.
Interactions
- Activated prothrombin complex concentrate increases risk of blood clots and thrombotic microangiopathy.
- Other clotting-factor medicines may affect bleeding management; specialist monitoring is important.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.